Cordicity
Request a demo



.

Patient-specific cardiac blood flow insights from standard CT imaging. CorASCT maps blood stagnation automatically — turning routine scans into a new clinical signal for stroke risk.

Request a demo→Join the team
Almi Invest
LiU InvestEast Sweden Capital
LEAD
Almi Invest
LiU InvestEast Sweden Capital
LEAD
Why it matters

Cardiac blood flow — a silent risk marker.

Deviated flow in the left atrium drives thrombus formation — the dominant mechanism behind ischemic stroke. Today's risk scores miss the patient. The signal lives in the scan.

0M+
Atrial fibrillation patients globally
5× folded stroke risk
0M+
Annual strokes worldwide
20% caused by AF
0M+
Living with post-stroke sequelae
Long-term disability burden
0B€+
Global economic burden
Healthcare + lost productivity
The solution

Introducing CorASCT.
More than improved imaging.

Automated blood stagnation mapping from a standard CT — a new quantitative marker for clinicians, designed for cloud-native distribution through existing PACS platforms.

01
Patient-specific

Computes hemodynamics per case — no population averages, no proxies.

02
Standard CT input

Works with any CT vendor and the systems that already exist in hospitals today.

03
Cloud-native

Delivered as an automated application integrated into PACS and AI marketplaces — without any manual intervention.

How it works

AI powered segmentation.

Not a render. The model identifies target cardiac structures from a routine CT, which are tracked over time and feed advanced hemodynamic computations.

Scene 01 · Whole heart
Scene 01 · Whole heart
01 / 04

This is the actual segmentation.

Not a render. The model identifies seven cardiac structures from a routine CT — the same data that feeds the hemodynamic computation in step 03.

Scene 02 · Left side
02 / 04

Where stasis matters.

The left atrium and left ventricle are the chambers where slow, recirculating blood drives thromboembolic risk. Cordicity quantifies stagnation here.

Scene 03 · Right side
03 / 04

Right-side anatomy, isolated.

Right atrium and right ventricle are segmented with the same model — enabling full four-chamber flow analysis when needed.

Scene 04 · Outflow tracts
04 / 04

Inflow and outflow, quantified.

Aorta and pulmonary artery boundaries define the flux surfaces. PV inflow and MV outflow are computed directly from these — step 03 takes over from here.

Book a demo
Use cases

Built for clinical impact
and scalable distribution.

Stroke care
Strengthen stroke origin assessments

Improve stroke care with patient-specific stagnation data when a cardioembolic origin is suspected — identify the silent high-risk patient.

Ablation therapy
Transforming atrial fibrillation ablation

Move beyond ablation for symptomatic AF patients and optimise resources — prioritise ablation for stroke risk reduction.

Anticoagulant decision
Decision support for treatment

Informed anticoagulation strategy and decisions with a new precision marker that complements existing clinical risk scores.

Market

A €4.5B opportunity hiding in plain sight.

CorASCT addresses converging clinical workflows across ablation therapy, stroke care and anticoagulation decisions — defining a meaningful addressable market for an integrated, CT-native solution.

Ablation priority
€1.0B
Stroke care
€1.5B
NOAC decision
€2.0B
TAM
€0.0B
Total addressable
SAM
€0.0B
Serviceable
SOM
€0M
5-year obtainable
Traction

Momentum across capital, clinic and channel.

Backed by leading Nordic investors and progressing toward integrated distribution through the imaging platforms clinicians already use — with an interdisciplinary team, strong IP and a maturing clinical evidence base.

IP
Strong patent applications filed
Market
Collaboration with leading distributors and hospitals
TRL
5
Research
Several high-impact publications
Team
Interdisciplinary expert founders
Investments
€700k+
Roadmap
2020–2023
Research
Strong research funding attracted
2023
Foundation
Key entrepreneurs in incubator programs
2024
Soft funding
Strong grant attraction
2025
Pre-seed round
€50k — LiU Invest
2026
Seed round
€650k — Almi Invest, East Sweden Capital et al.
2027
Pre-Series A
Clinical studies & MDR 2A path
2028
Clinical launch
CorASCT · MDR 2A clearance
2029
Scaling
NAM expansion · FDA clearance
Team

Clinicians, computational scientists and entrepreneurs.

Operational team

Linus Ohlsson, MD, PhD
Linus Ohlsson, MD, PhD
Co-founder · CEO
Jonas Lantz, PhD
Jonas Lantz, PhD
Co-founder · CTO
Tino Ebbers, Prof.
Tino Ebbers, Prof.
Co-founder · CSO
Erik Birgersson, MSc
Erik Birgersson, MSc
Software Engineer
Bild kommer
Felix Wennerstein
Junior market analyst
Bild kommer
Lowisa Nilsson, MSc
R&D Engineer

Board

Bild kommer
Gunilla Åberg
Acting chairman
Bild kommer
Matts Karlsson, Prof.
Board member
Bild kommer
Anders Persson, Prof.
Board member
Bild kommer
Åsa Wallin
Board member
Bild kommer
Björn Persson
Board member
We are hiring
Join the people rewriting cardiac risk.

We are recruiting a senior software engineer to help scale CorASCT — join a small, interdisciplinary team building the next quantitative marker in stroke care.

Cordicity

More than improved imaging.

Talk to the team building the next quantitative marker in stroke care — whether you are a clinician, a partner, an investor or a future colleague.

Request a demo→Partner with us